An observational study in Cardiovascular Diseases and Lung Diseases, sponsored by Karolinska Institutet. Recruiting at 6 sites in Sweden. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Karolinska Institutet · Observational
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.
In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and lung disease in the general population by identifying novel risk markers. This is also the purpose of SCAPIS 2, which further aims to gain important insights into risk factors and longitudinal development of heart, vascular and lung diseases such as atherosclerosis and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study participants approximately 8-10 years after the baseline examination SCAPIS 1.
The five overall objectives of SCAPIS 2 are:
SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline examination (SCAPIS 1) study population approximately 8-10 years after their initial participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were drawn from each recruitment area in the Swedish population registry until approximately 30 000 subjects were included. The final number was 30 154 subjects with an even sex and age distribution. The original recruitment process ensured that the study population in SCAPIS 1 was representative for the Swedish population in general.
An invitation letter with brief information about SCAPIS 2 will be sent to randomly selected individuals by mail, including phone number and e-mail address to the study center. The invitation letter will refer to a study webpage where the subjects can indicate if they are interested in participating in SCAPIS 2 and read the subject information in advance (voluntary). The invitation also includes contact information to the study center to be used if the subject prefers to not use the web page or has questions. Subjects that have moved since their participation in SCAPIS 1 will be invited to the same study center as their baseline examination.
The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever possible, all visits should be performed within a period of 4 weeks. Examinations that are common for all sites include:
Computed tomography (CT)
All subjects will be fasting overnight (at least 8 hours) before the first visit. If a subject has not been fasting overnight, blood sampling should be rescheduled and performed preferably at an extra visit but no later than Visit 2. For subjects with elevated plasma glucose levels, an overnight fasting glucose measurement will be repeated.
Subjects should be instructed to take their regular medication as usual also when fasting. The only medication that should not be taken is medication for diabetes, per oral as well as injections. Subjects with diabetes should be fasting as all other subjects and should bring their medication to take when having breakfast at the clinic. To obtain standardized conditions for the CT examination, subjects are recommended to be fasting for at least 4 hours before intake of a standardized meal. The standardized meal should be consumed 2 hours before the CT scan.
All clinical findings and assessment of risk should be taken care of according to current guidelines and SCAPIS manual.
5,025 studies on the registry are indexed under Cardiovascular Diseases; 930 are open to participants now.
This study's planned enrollment of 30,154 is above the median of 600 across 1,524 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Karolinska Institutet is the lead sponsor of 1,145 studies on the registry; 274 are open to participants now.
Counted across the registry records on this site, refreshed daily.
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.
In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participated in SCAPIS 1.
Exclusion Criteria:
Cardiovascular death, non-fatal myocardial infarction or stroke.
Cardiovascular death, non-fatal myocardial infarction or stroke.
Time frame: Through study completion, an average of 5 years
Cardiovascular death or non-fatal myocardial infarction
Cardiovascular death or non-fatal myocardial infarction
Time frame: Through study completion, an average of 5 years
Cardiovascular death
Cardiovascular death
Time frame: Through study completion, an average of 5 years
Myocardial infarction (fatal or non-fatal)
Myocardial infarction (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Stroke (fatal or non-fatal)
Stroke (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Death (all-cause)
Death (all-cause)
Time frame: Through study completion, an average of 5 years
Unstable angina requiring revascularization
Unstable angina requiring revascularization
Time frame: Through study completion, an average of 5 years
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Time frame: Through study completion, an average of 5 years
Lung cancer
Lung cancer
Time frame: Through study completion, an average of 5 years
Plan to share: Yes — Individual participant data can be shared if approved the Swedish Ethical Review Authority and authority responsible for personal data
Supporting information: Study protocol, Informed consent form
Time frame: After study completion
Access criteria: Approval from the Swedish Ethical Review Authority and authority responsible for personal data
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.